The American pharmaceutical company Moderna has announced the launch of a booster dose trial of the vaccine to combat the Omega Crohn's variant of the corona virus.
According to the AFP news agency, the modern company announced on Wednesday that clinical trials of the booster dose would be conducted on 600 adults, half of whom had received two doses of the modern vaccine at least six months ago, while half Has been given a booster dose in addition to two doses.
The new booster dose of the Moderna vaccine is specifically designed to compete with the Omi Cron variant, the efficacy of which will be assessed as the third and fourth dose.The Moderna company has also reported on the effectiveness of the previously approved booster diet against the Omi Cron variant. The company had said that 29 days after the booster dose, the human body's antibodies against the omega-Cron were six times lower than those produced six months later. However, six months after the injection, antibodies can still be detected in the human body.
The data came from research on blood samples from 20 people who were given a booster dose of 50 micrograms.
Stephen Bansell, head of Moderna Company, said in a statement that the approved booster dose is effective against Omi Cron for six months.
He added that a special booster shot has been developed for this variant, keeping in view the long-term threat of Omi Kron, the second phase of the study has begun.
A day before the statement from Moderna, Pfizer announced that it had begun recruiting people to take part in clinical trials of vaccines designed to treat Omi Crohn's disease.
Note that the Moderna and Pfizer vaccines have been developed using RNA technology, which makes it much easier to adapt the vaccine to the changing type of virus.
